LIXT Stock Price, Lixte Biotechnology Holdings, . Quote, Chart

Market Summary

USD2.46+0.08

Delayed

3.36%

LIXT Stock Price

View Fullscreen

LIXT RSI Chart

LIXT Valuation

Market Cap

5.5M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

316.44

Price/Free Cashflow

-1.45

LIXT Price/Sales (Trailing)

LIXT Profitability

Return on Equity

-150.04%

Return on Assets

-130.69%

Free Cashflow Yield

-68.88%

LIXT Fundamentals

LIXT Revenue

Revenue (TTM)

17.5K

Rev. Growth (Yr)

-42.99%

Rev. Growth (Qtr)

-27.38%

LIXT Earnings

Earnings (TTM)

-4.7M

Earnings Growth (Yr)

28.98%

Earnings Growth (Qtr)

5.9%

Breaking Down LIXT Revenue

Last 7 days

-3.9%

Last 30 days

-26.1%

Last 90 days

-11.8%

Trailing 12 Months

272.7%

How does LIXT drawdown profile look like?

LIXT Financial Health

Current Ratio

7.75

LIXT Investor Care

Shares Dilution (1Y)

35.02%

Diluted EPS (TTM)

-2.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q4
2024	0	0
2023	14.3K	17.5K
2022	0	11.2K
2021	0	0
2020	0	0
2019	0	0
2018	0	0
2017	0	0
2016	0	0
2015	0	200.0K
2010	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lixte Biotechnology Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 03, 2023	bernards rene	bought	13,872	2.51	5,527	-
Oct 03, 2023	van der baan bastiaan jeroen	bought	28,000	2.8	10,000	president and ceo
Oct 02, 2023	bernards rene	bought	10,243	2.29	4,473	-
Dec 30, 2022	van der baan bastiaan jeroen	bought	4,900	0.49	10,000	-
Dec 30, 2022	van der baan bastiaan jeroen	bought	49,000	4.9	10,000	-
Dec 15, 2022	bernards rene	bought	7,650	0.51	15,000	-
Dec 12, 2022	bernards rene	bought	6,100	0.61	10,000	-
Dec 09, 2022	forman eric	bought	9,836	0.61048	16,112	vice president and coo

Which funds bought or sold LIXT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	76.02	8,059	13,321	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	5.00	5.00	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	7,319	24,018	-%
May 13, 2024	UBS Group AG	added	1,734	185	193	-%
May 13, 2024	UBS Group AG	sold off	-100	-7.00	-	-%
May 13, 2024	CLEAR STREET LLC	reduced	-0.43	-	1,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	9.00	30.00	-%
May 08, 2024	Ethos Financial Group, LLC	new	-	84,000	84,000	0.02%
May 06, 2024	HighTower Advisors, LLC	unchanged	-	102,000	336,000	-%
May 06, 2024	Warberg Asset Management LLC	unchanged	-	515	2,048	-%

Are Funds Buying or Selling LIXT?

Are funds buying LIXT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIXT

No. of Funds

Unveiling Lixte Biotechnology Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 07, 2022	forman eric	075%	1,104,431	SC 13G/A
Apr 07, 2022	krinsky glenn	10.73%	1,474,998	SC 13G
Jan 04, 2022	sabby management, llc	12.%	0	SC 13G/A
Mar 03, 2021	sabby management, llc	7.99%	1,081,081	SC 13G
Dec 17, 2020	greenberg robert	11.15%	1,380,264	SC 13G/A
Dec 17, 2020	forman eric	11.38%	1,417	SC 13G/A
Dec 17, 2020	schwartzberg gil	16.2%	2,144,985	SC 13G/A
Dec 17, 2020	ho hung tak	8.73%	1,084,210	SC 13G/A
Dec 17, 2020	kovach john s	12.6%	1,561,283	SC 13D/A

Recent SEC filings of Lixte Biotechnology Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 03, 2024	424B5	Prospectus Filed
May 03, 2024	424B5	Prospectus Filed
May 02, 2024	EFFECT	EFFECT
Apr 30, 2024	S-3/A	S-3/A
Apr 23, 2024	S-3	S-3
Mar 28, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report

Peers (Alternatives to Lixte Biotechnology Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Lixte Biotechnology Holdings, Inc. News

Latest updates

Lixte Biotechnology Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-27.4%	3.00	4.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-5.8%	967	1,026	1,370	1,633	1,479	1,546	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	320	519	584	644	754	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-20.1%	119	149	189	454	272	165	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-29.2%	7.00	10.00	4.00	4.00	2.00	627*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	5.9%	-971	-1,032	-1,367	-1,631	-1,478	-1,546	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	7.8%	-268.25*	-290.92*	-420.02*	-563.87*	-33.55*	-32.36*	-33.64*	-28.03*	-29.84*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	12.5%	-789	-902	-1,271	-1,208	-1,173	-1,194	-1,146	-927	-1,041	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-16.7%	3,589	4,309	5,235	3,095	4,331	5,561	6,819	8,024	4,118	5,093	6,334	7,243	7,890	5,228	1,362	1,892	2,276	2,672	3,066	3,619	3,955
Current Assets	-16.7%	3,589	4,309	5,235	3,095	4,331	5,561	6,819	8,024	4,107	5,093	6,307	7,243	7,890	5,228	1,188	1,805	2,276	2,672	3,066	3,619	3,955
Cash Equivalents	-18.8%	3,414	4,203	5,106	2,913	4,088	5,353	6,562	7,736	3,778	4,824	5,961	6,798	7,739	5,069	1,076	1,774	2,185	2,599	2,976	3,564	3,894
Current Liabilities	47.5%	463	314	312	403	250	396	408	532	645	303	259	376	242	217	221	214	225	238	309	223	245
Shareholder's Equity	-21.7%	3,126	3,995	4,923	2,693	4,081	5,165	6,411	7,492	3,473	4,790	6,075	6,866	7,648	5,012	1,141	1,678	2,051	2,434	2,756	3,396	3,710
Retained Earnings	-2.0%	-49,453	-48,481	-47,449	-46,430	-44,762	-43,394	-41,763	-40,285	-38,739	-37,082	-35,052	-33,814	-32,080	-30,353	-29,446	-27,845	-27,472	-27,088	-26,766	-25,687	-25,077
Additional Paid-In Capital	0.2%	49,079	48,976	48,872	45,623	45,342	45,060	44,673	44,276	38,711	38,371	37,626	37,179	36,227	31,864	27,081	26,016	26,016	26,022	26,016	25,577	25,281
Shares Outstanding	0%	2,249	2,249	2,249	1,666	1,666	1,665	1,665	1,620	1,375	1,375	1,338	1,363	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,125	-	-	-	2,400	-	-	-	30,550	-	-	-	13,193	-	-	-	14,659	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	12.5%	-789	-902	-944	-1,175	-1,271	-1,208	-1,173	-1,194	-1,035	-1,146	-927	-1,041	-1,026	-739	-623	-354	-414	2,971	-587	-329	-379
Share Based Compensation	-100.0%	-	104	112	280	277	385	397	424	340	347	347	-	656	-37.85	464	-	-	-33.00	32.00	-	-
Cashflow From Financing	-	-	-	3,137	-	6.00	-	-	5,152	-10.91	10.00	90.00	101	3,696	4,732	-74.39	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LIXT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues
General and administrative costs:
Compensation to related parties, including stock-based compensation of $102,927 and $276,980 for the three months ended March 31, 2024 and 2023, respectively	317,662	519,480
Patent and licensing legal and filing fees and costs	83,211	317,340
Other costs and expenses	446,942	344,242
Research and development costs	119,064	189,085
Total costs and expenses	966,879	1,370,147
Loss from operations	(966,879)	(1,370,147)
Interest income	2,859	5,015
Interest expense	(7,186)	(3,861)
Foreign currency gain (loss)	(116)	1,334
Net loss	$ (971,322)	$ (1,367,659)
Net loss per common share basic	$ (0.43)	$ (0.82)
Net loss per common share diluted	$ (0.43)	$ (0.82)
Weighted average common shares outstanding basic	2,249,290	1,664,951
Weighted average common shares outstanding diluted	2,249,290	1,664,951

LIXT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 3,414,263	$ 4,203,488
Advances on research and development contract services	78,016	78,016
Prepaid insurance	22,794	17,116
Other prepaid expenses	74,130	10,000
Total current assets	3,589,203	4,308,620
Total assets	3,589,203	4,308,620
Current liabilities:
Accounts payable and accrued expenses, including $38,819 and $36,250 to related parties at March 31, 2024 and December 31, 2023, respectively	246,687	156,758
Research and development contract liabilities	216,149	157,100
Total current liabilities	462,836	313,858
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares at March 31, 2024 and December 31, 2023	3,500,000	3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares at March 31, 2024 and December 31, 2023	225	225
Additional paid-in capital	49,079,192	48,976,265
Accumulated deficit	(49,453,050)	(48,481,728)
Total stockholders’ equity	3,126,367	3,994,762
Total liabilities and stockholders’ equity	$ 3,589,203	$ 4,308,620

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

CEO	Dr. John S. Kovach M.D.
WEBSITE	https://lixte.com
INDUSTRY	Biotechnology
EMPLOYEES	3

Lixte Biotechnology Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Lixte Biotechnology Holdings, Inc.? What does LIXT stand for in stocks?

LIXT is the stock ticker symbol of Lixte Biotechnology Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lixte Biotechnology Holdings, Inc. (LIXT)?

As of Fri May 17 2024, market cap of Lixte Biotechnology Holdings, Inc. is 5.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIXT stock?

You can check LIXT's fair value in chart for subscribers.

What is the fair value of LIXT stock?

You can check LIXT's fair value in chart for subscribers. The fair value of Lixte Biotechnology Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lixte Biotechnology Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIXT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lixte Biotechnology Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether LIXT is over valued or under valued. Whether Lixte Biotechnology Holdings, Inc. is cheap or expensive depends on the assumptions which impact Lixte Biotechnology Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIXT.

What is Lixte Biotechnology Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LIXT's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 316.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIXT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lixte Biotechnology Holdings, Inc.'s stock?

In the past 10 years, Lixte Biotechnology Holdings, Inc. has provided 0.33 (multiply by 100 for percentage) rate of return.